Supplements

Cannabis-based medicinal products improve sleep quality in autistic adults over 18 months

In an observational case series of 130 autistic adults from the UK Medical Cannabis Registry, sleep quality as measured by the SQS improved significantly from baseline to 18 months (p < 0.001). The study also found improvements in anxiety and health-related quality of life, but these are associations due to the lack of a control group.

1 min read•Updated Jul 7, 2026•0 RCTs•View structured evidence →
Evidence Score34/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Cannabis-based medicinal products improve sleep quality in autistic adults over 18 months The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).

The Claim

Cannabis-based medicinal products improve sleep quality in autistic adults over 18 months

This conclusion is most relevant to: Autistic adults (n=130) from the UK Medical Cannabis Registry.

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder. (Neuropsychopharmacology reports, 2026) — In an observational case series of 130 autistic adults from the UK Medical Cannabis Registry, sleep quality as measured by the SQS improved significantly from baseline to 18 months (p < 0.001). The study also found improvements in anxiety and health-related quality of life, but these are associations due to the lack of a control group.

How It Works

The proposed biological pathway:

  • ▸CBMPs interact with the endocannabinoid system
  • ▸Modulation of neurotransmitter release (e.g., GABA, serotonin)
  • ▸Reduction in anxiety and distressed behaviors
  • ▸Improvement in sleep quality

Who Might Benefit

Evidence fit by population:

  • ▸Autistic adults (n=130) from the UK Medical Cannabis Registry

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Observational design with no control group, so results are associations not causal effects
  • ▸Potential selection bias from registry data and lack of blinding
  • ▸High rate of adverse events (19.23% of participants reported 232 events), though mostly mild or moderate

Frequently Asked Questions

What sleep measure was used in this study?▼

The study used the Single-Item Sleep Quality Scale (SQS) to assess sleep quality.

How long did the sleep improvements last?▼

Improvements were observed over an 18-month follow-up period.

Were there any side effects from cannabis-based treatments?▼

Yes, 19.23% of participants reported adverse events, with most being mild (67.69%) or moderate (76.15%).

Can these results be considered proof that cannabis improves sleep in autism?▼

No, because the study lacked a control group, so the findings are associations, not proven treatment effects.

References

  1. 1.Aggarwal A, Erridge S, Varadpande M, Clarke E, McLachlan K, Coomber R, Asghar M, Bhoskar U, Crews M, De Angelis A, Imran M, Kamal F, Korb L, Mwimba G, Sachdeva-Mohan S, Shaya G, Rucker JJ, Sodergren MH. “UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder..” Neuropsychopharmacology reports, 2026. PMID: 42387975 DOI: 10.1002/npr2.70146
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.